Fig. 6

Human breast cancer xenografts exhibit quiescence following targeted therapy. a Schematic of generation of xenograft primary tumors and MRLs following targeted therapy. b Tumor volumes in mice treated with vehicle control or the combination of lapatinib (L), trastuzumab (T), pertuzumab (P), and estrogen deprivation (ED). c IF staining for Ki67, GFP, and Hoechst 33258 on sections of BT474M1-GFP primary tumor (left), or residual disease (right). d IF staining for CD31, GFP, and Hoechst 33258, on sections of BT474M1-GFP primary tumor (left) or residual lesion (right), showing CD31 alone (top), or CD31 in combination with GFP and Hoechst 33258 (bottom). e Quantification of GFP-labeled BT474M1 tumor cells staining positive for Ki67 from c, on sections from primary tumors (PT) or residual lesions (RL). f, g IF staining for collagen type-I (f) and fibronectin (g) on sections of orthotopic BT474M1-GFP residual lesions. ***p value vs. primary tumor cells < 0.001. Scale bars (c, f, g) 50 μm and (d) 100 μm